Jared Kelly Biography and Net Worth

Chief Executive Officer & Director of Oncolytics Biotech

Jared Kelly is an accomplished lawyer and executive with a distinguished career in corporate law, particularly within the biotechnology sector. Mr. Kelly recently served as head of legal and corporate strategy at Ambrx and played a central role in its $2 billion sale to Johnson & Johnson. He has managed numerous transactions in the biotech space for companies at various stages of development. After leaving Ambrx, he has served as an advisor to multiple public and private drug development and pharmaceutical companies. Prior to becoming a biotech executive, Mr. Kelly was a sought-after public company lawyer who began his career with Kirkland & Ellis LLP, where he represented various public companies in securities offerings, IPOs and merger transactions. He also served as a partner at Lowenstein Sandler LLP, where his practice focused on representing biotechnology companies in financing transactions, mergers and acquisitions, and other complex transactions. Mr. Kelly received his J.D. and an LL.M. in Securities and Financial Regulation from Georgetown University Law Center, where he was the recipient of multiple honors and fellowships, including the Lane Evans Fellowship and Decrane Scholarship.

What is Jared Kelly's net worth?: The estimated net worth of Jared Kelly is at least $97.70 thousand as of March 12th, 2026. Mr. Kelly owns 114,050 shares of Oncolytics Biotech stock worth more than $97,695 as of August 28th. This net worth evaluation does not reflect any other assets that Mr. Kelly may own. Learn More about Jared Kelly's net worth.
How do I contact Jared Kelly?: The corporate mailing address for Mr. Kelly and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on Jared Kelly's contact information.
Has Jared Kelly been buying or selling shares of Oncolytics Biotech?: Jared Kelly has not been actively trading shares of Oncolytics Biotech in the last ninety days. Most recently, on Thursday, March 12th, Jared Kelly bought 5,050 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $0.96 per share, with a total value of $4,848.00. Following the completion of the transaction, the chief executive officer now directly owns 114,050 shares of the company's stock, valued at $109,488. Learn More on Jared Kelly's trading history.
Who are Oncolytics Biotech's active insiders?: Oncolytics Biotech's insider roster includes Andrew Aromando (Chief Business Officer), Deborah Brown (Director), Allison Hagerman (Chief Technology Officer), Jared Kelly (Chief Executive Officer & Director), James Parsons (Director), and Bernd Seizinger (Director). Learn More on Oncolytics Biotech's active insiders.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

Jared Kelly Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2026	Buy	5,050	$0.96	$4,848.00	114,050
2/12/2026	Buy	29,500	$0.84	$24,780.00	109,000
2/11/2026	Buy	5,600	$0.84	$4,704.00	79,500

Jared Kelly Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.86

$0.82

$0.86

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.86

$0.73

$1.51

Volume

672,836 shs

Average Volume

1,275,661 shs

Market Capitalization

$109.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13